Protein Largen
Introduction
Section titled “Introduction”Protein largen refers to a class of proteins whose circulating plasma levels are significantly influenced by common genetic variations. These proteins are often categorized as protein quantitative trait loci (pQTLs), reflecting that their abundance in biological fluids is a measurable trait affected by an individual’s genetic makeup. [1]Understanding the genetic determinants of protein levels provides insights into biological pathways and potential disease mechanisms.[1]
Biological Basis
Section titled “Biological Basis”The biological basis of protein largenrelates to the intricate regulation of protein expression, modification, and degradation within the human body. Genome-wide association studies (GWAS) have demonstrated that common single nucleotide polymorphisms (SNPs) can exert strong effects on protein levels, often acting incis (near the gene coding for the protein) or sometimes in trans (at a distant genomic location). [1] These genetic variations can affect protein function or quantity, which in turn can impact a wide range of physiological processes. For instance, genetic variations have been shown to influence levels of liver enzymes, inflammatory cytokines, chemokines, adipokines, and proteins involved in lipid metabolism. [1]
Clinical Relevance
Section titled “Clinical Relevance”The clinical relevance of protein largen is substantial, as variations in protein levels are often linked to the risk and progression of numerous diseases. Plasma levels of liver enzymes, for example, are routine diagnostic and monitoring tools for liver diseases and drug treatment responses. [2]Similarly, proteins involved in lipid metabolism, such as those impacting HDL, LDL, and triglyceride concentrations, are directly relevant to the risk of coronary artery disease and dyslipidemia.[3]Inflammatory proteins like C-reactive protein (CRP) and Monocyte Chemoattractant Protein-1 (MCP1) are biomarkers for inflammation and cardiovascular risk.[4] Adipokines and chemokines are implicated in metabolic conditions and immune responses, including HIV progression. [1]Identifying genetic factors that influence these protein levels can help in assessing disease susceptibility, predicting drug responses, and personalizing treatment strategies.[2]
Social Importance
Section titled “Social Importance”The social importance of studying protein largenlies in its potential to advance public health through a deeper understanding of human biology and disease. By elucidating how genetic variations influence protein levels, researchers can identify novel therapeutic targets, develop more accurate diagnostic tools, and contribute to preventive medicine efforts. This knowledge can facilitate the development of personalized medicine approaches, where treatments are tailored to an individual’s genetic profile and predicted protein responses. Ultimately, research into pQTLs andprotein largenaims to improve the diagnosis, treatment, and prevention of widespread conditions such as cardiovascular disease, metabolic disorders, and inflammatory diseases, thereby enhancing overall population health.[1]
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Studies investigating protein largen faced several methodological and statistical constraints that could impact the interpretation of findings. The moderate sample sizes in some cohorts limited statistical power, increasing the susceptibility to false negative findings and making it difficult to detect associations with modest effect sizes.[5] Furthermore, the inherent challenge of genome-wide association studies (GWAS) involves sorting through numerous associations, and without external replication, there is a risk of reporting false positive findings due to the multiple statistical tests performed. [5] This is compounded by the use of limited SNP coverage in earlier GWAS platforms, which may have missed some true genetic associations due to a lack of comprehensive genomic coverage. [6]
Moreover, certain analyses were constrained by study design choices, such as performing only sex-pooled analyses to manage the multiple testing burden, which could lead to undetected sex-specific associations with protein largen.[6] The primary reliance on an additive genetic model in some analyses also means that other potentially relevant genetic models were not explored, potentially overlooking complex genetic effects. [1] Additionally, the definition of statistical significance in genome-wide scans remains complex, involving a degree of estimation for a priori probabilities and study power, which can influence the thresholds applied for declaring significant associations. [7]
Phenotype Definition and Generalizability
Section titled “Phenotype Definition and Generalizability”Challenges in phenotype definition and measurement also posed limitations for studies on protein largen. Many protein levels exhibited non-normal distributions, necessitating various complex statistical transformations to approximate normality, which can influence the statistical models and interpretation.[1] For several proteins, a notable percentage of individuals had levels below detectable limits, requiring traits to be dichotomized, potentially leading to a loss of quantitative information and reduced statistical power. [1] In the case of LipoproteinA, a standard clinical cutoff was used to dichotomize the trait when normal distribution could not be achieved through transformation. [1]
Generalizability of findings is another key concern, as many primary studies were conducted predominantly in populations of white European ancestry, such as the Framingham Heart Study cohort and replication cohorts. [1] While efforts were made to correct for population stratification in some analyses, the predominantly homogenous ancestry limits the direct applicability of these findings to diverse ethnic groups. [8]Confounding factors like lipid-lowering therapies also needed careful consideration, with some studies excluding individuals on such medications, highlighting the potential for environmental or treatment effects to influence observed protein largen levels.[9]
Translational Gaps and Unexplained Variation
Section titled “Translational Gaps and Unexplained Variation”Despite identifying numerous genetic associations, significant translational gaps and remaining knowledge persist for protein largen. The ultimate validation of genetic findings requires replication in independent cohorts and subsequent functional studies to pinpoint the specific functional variants responsible and elucidate their biological mechanisms.[5]Without such follow-up, it remains challenging to definitively ascertain whether reported associations represent true positive genetic effects or to prioritize specific single nucleotide polymorphisms (SNPs) for further investigation.[5]
Furthermore, studies indicate that even robust genetic associations explain only a fraction of the phenotypic variance for certain traits, implying that a substantial portion of the heritability, often referred to as “missing heritability,” remains unexplained. [10] This unexplained variation may be attributed to a multitude of factors, including rarer variants, complex gene-gene or gene-environment interactions not fully captured by current models, or other unmeasured environmental confounders. [5] The identification of cis-acting effects as often the strongest suggests that trans-acting effects, while potentially important, require further dedicated investigation. [1]
Variants
Section titled “Variants”The genetic variants rs144516014 and rs10754199 are located in or near genes that play fundamental roles in cell regulation, protein homeostasis, and immune system function. Understanding their implications requires examining the functions of their respective genes, LIN54 and COPS4 for rs144516014 , and CFH for rs10754199 . These genes are integral to processes that broadly influence the cellular environment and the activity of a wide range of proteins throughout the body, ultimately impacting overall protein function and abundance, which can be thought of as contributing to the “protein largeness” or complexity of biological systems. [1]
The variant rs144516014 is associated with the LIN54 and COPS4 genes. LIN54 is a component of the DREAM complex, a transcriptional repressor that precisely controls cell cycle-dependent gene expression, particularly those essential for quiescent (G0), G1, and G2/M phases. By regulating which genes are turned on or off during these critical cellular transitions, LIN54 directly impacts the production of numerous proteins, influencing cell proliferation and differentiation. [5] Similarly, COPS4 is part of the COP9 signalosome (CSN) complex, a key regulator of ubiquitin-proteasome system. The CSN complex de-ubiquitinates cullin-RING ubiquitin ligases (CRLs), thereby stabilizing their substrates and influencing protein degradation pathways. Variations like rs144516014 within or near these genes could alter their regulatory capacities, potentially leading to dysregulated protein expression or stability, and thus affecting cellular protein levels and cellular processes like growth and repair.
The variant rs10754199 is linked to the CFH gene, which encodes Complement Factor H. This protein is a crucial soluble regulator of the alternative pathway of the complement system, a vital part of innate immunity. CFH protects host cells from complement-mediated damage by inhibiting the formation and accelerating the decay of the C3 convertase enzyme on cell surfaces. [4] It ensures that the complement system targets pathogens effectively while sparing healthy tissues. Polymorphisms in CFH, such as rs10754199 , can impact the efficiency of this regulation, potentially leading to aberrant complement activation, which has been implicated in various inflammatory and autoimmune conditions. Such changes could alter the balance of complement proteins, impacting the immune response and the overall protein landscape involved in defense mechanisms.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs144516014 | LIN54 - COPS4 | protein largen measurement |
| rs10754199 | CFH | CD63 antigen measurement glutaminyl-peptide cyclotransferase-like protein measurement protein measurement stabilin-1 measurement serine palmitoyltransferase 2 measurement |
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Definition and Quantitative Trait Characteristics of Protein Largen
Section titled “Definition and Quantitative Trait Characteristics of Protein Largen”Protein largen is primarily defined as a quantitative trait, meaning its concentration or activity levels within biological samples can be measured along a continuous scale. [1] This allows for precise assessment of individual variations, which are often indicative of underlying physiological states or genetic influences. [1] Conceptually, similar to other proteins, protein largenmay function as an “intermediate phenotype,” serving as a measurable biomarker that links genetic variations to more complex metabolic or cardiovascular outcomes.[11] Its operational definition typically involves the quantification of its levels in serum or plasma, with data often transformed to achieve normality for statistical analyses, such as the use of cube root transformations or conversion to Z scores representing percentiles in a normal distribution. [12]
Measurement Criteria and Categorization of Protein Largen Levels
Section titled “Measurement Criteria and Categorization of Protein Largen Levels”Measurement of protein largen levels relies on specific assay methodologies, which inherently possess both lower and upper detection limits. [1] Values falling below detectable limits are commonly coded as zero, while those exceeding the upper limits are treated appropriately in non-parametric analyses to ensure their inclusion does not skew results. [1] For analytical purposes, protein largen may be classified using diagnostic and measurement criteria such as clinical cut-off points, which dichotomize levels into categories like “high” and “low”. [1] This categorical approach is useful for identifying individuals at potential risk or for simplifying complex quantitative data in genome-wide association studies, often achieved by dichotomizing traits at the median or at specific clinical thresholds. [1] Furthermore, statistical adjustments for covariates such as age, sex, BMI, and other factors are routinely applied during analyses to ensure the observed protein largen levels reflect intrinsic variations rather than confounding influences. [12]
Terminology and Clinical Relevance of Protein Largen
Section titled “Terminology and Clinical Relevance of Protein Largen”The study of protein largen often employs specific terminology, including its identification as a target in “protein quantitative trait loci (pQTLs)” research, which investigates genetic variants influencing protein levels. [1] Standardized nomenclature for proteins, such as accession numbers from databases like Swissprot, facilitates consistent identification and cataloging of protein largen across various studies. [1] Clinically and scientifically, understanding protein largenlevels and their genetic determinants is significant because variations in plasma protein concentrations are frequently associated with various metabolic and cardiovascular diseases.[4] Therefore, protein largenserves as a crucial biomarker, and its precise definition, measurement, and classification are fundamental for deciphering its role in health and disease progression.
Biological Background
Section titled “Biological Background”Genetic Regulation of Protein Abundance
Section titled “Genetic Regulation of Protein Abundance”The abundance of proteins within the human body is a fundamental biological trait, largely governed by an individual’s genetic makeup. Following the central dogma, DNA sequences are transcribed into RNA, which is then translated into proteins; thus, variations in DNA can profoundly influence protein levels. [1] Genome-wide association studies have identified protein quantitative trait loci (pQTLs), which are specific DNA variants associated with differences in the circulating levels of particular proteins. [1] These genetic effects can be substantial, with some common variants influencing protein levels by 0.19 to 0.69 standard deviations per allele, highlighting a direct link between genotype and proteome composition. [1]
Genetic mechanisms underpinning these variations include altered rates of gene transcription, as observed for GGT1, where specific alleles may dictate how much mRNA is produced, and consequently, how much protein is synthesized. [1] Furthermore, variations in gene copy number, such as those seen in CCL4, can directly impact protein availability by increasing or decreasing the number of gene templates for transcription. [1] Transcription factors, such as HNF1A, play a critical role by binding to gene promoters and regulating their activity, thereby influencing the expression of proteins like C-reactive protein through synergistic trans-activation. [13] Additionally, the presence of common null alleles, as exemplified by GSTM1 and GSTT1, can lead to a complete absence of their respective protein products, demonstrating the diverse ways genetic variation shapes protein landscapes. [1]
Cellular and Molecular Determinants of Protein Levels
Section titled “Cellular and Molecular Determinants of Protein Levels”Beyond transcriptional regulation, the final concentration of a protein is meticulously controlled by a series of cellular and molecular processes, including post-transcriptional and post-translational modifications. For instance, the levels of certain proteins are modulated by their rates of cleavage, as observed with the soluble IL6R receptor, where genetic variants can influence the shedding of its bound form. [1] Similarly, the efficiency of protein secretion from cells into the bloodstream, a critical determinant for circulating protein levels, can be genetically influenced, as demonstrated by the varying secretion rates of different-sized LPA proteins. [1] These mechanisms ensure a dynamic regulation of protein availability, impacting their functional capacity within tissues and circulation.
Post-translational modifications, particularly glycosylation, play a significant regulatory role in protein function and stability. Enzymes like polypeptide N-acetylgalactosaminyltransferase 2, encoded by GALNT2, are crucial for O-linked glycosylation, attaching N-acetylgalactosamine to proteins, which can alter their activity or half-life. [9] The presence of specific glycan structures, such as sialylated complex-type N-glycans, can enhance the signaling capabilities of proteins like soluble ICAM-1, further underscoring the importance of these modifications in cellular communication and function. [8]Plasma proteins like alpha 2-macroglobulin and von Willebrand factor can also carry covalently linkedABO(H) histo-blood group antigens, implying a complex interplay between genetic factors and the biochemical landscape. [8] Enzymes such as fatty acid delta-5 desaturase (FADS1) and lipoprotein lipase (LPL) further illustrate how specific enzymes are central to metabolic pathways, influencing the profiles of fatty acids and lipid-carrying particles, which in turn can impact the synthesis or modification of other proteins. [14]
Systemic Impact on Metabolism and Homeostasis
Section titled “Systemic Impact on Metabolism and Homeostasis”The collective abundance of proteins extends its influence throughout the body, critically impacting systemic metabolism and maintaining physiological homeostasis across various tissues and organs. Proteins like LCAT (lecithin-cholesterol acyltransferase) are central to lipid metabolism, affecting the concentrations of cholesterol and triglycerides, which are vital for cellular integrity and energy storage. [3] Similarly, the MLXIPLgene is associated with plasma triglyceride levels, highlighting its role in lipid regulation and energy balance.[9] Enzymes such as FADS1 and LIPCare key players in the metabolism of long-chain fatty acids, influencing the synthesis of crucial biomolecules like arachidonic acid and other polyunsaturated fatty acids, which are integral to cell membrane structure and signaling pathways.[14]
Furthermore, specific proteins exhibit organ-specific effects or contribute to systemic regulation. Akp2(alkaline phosphatase 2), for instance, is involved in regulating enzyme activity within the liver, impacting metabolic functions in this vital organ.[2] SLC2A9plays a significant role in influencing uric acid concentrations, with notable sex-specific effects, demonstrating how protein function can vary between biological sexes and impact waste product excretion.[15] NCAN (neurocan), a proteoglycan, is specific to the nervous system, where it is involved in neuronal pattern formation, network remodeling, and synaptic plasticity, illustrating the diverse functional roles proteins hold within complex biological systems. [3] The interplay of these proteins contributes to overall health, with disruptions leading to homeostatic imbalances.
Protein Variation in Pathophysiology and Disease
Section titled “Protein Variation in Pathophysiology and Disease”Variations in protein levels, often influenced by pQTLs, are intimately linked to pathophysiological processes and the predisposition to numerous diseases. For example, blood levels of C-reactive protein (CRP), a well-known inflammatory marker, are associated with various metabolic and cardiovascular diseases, and genetic variants nearHNF1A, IL6R, and GCKR can influence its plasma concentration. [4] Similarly, proteins such as IL18 and IL1RN are components of the immune system, and their altered levels, influenced by genetic factors, can impact inflammatory responses. [1]Understanding these genetic determinants provides insight into disease susceptibility and progression.
Beyond inflammatory responses, alterations in protein profiles are implicated in metabolic and developmental disorders. LPL(lipoprotein lipase) plays a crucial role in fat transport and breakdown, and its mass correlates significantly with insulin sensitivity and adiponectin levels, linking protein abundance to the risk of metabolic syndromes.[12] Rare genetic variants in LCAT, a protein essential for lipid metabolism, are known to considerably affect lipid concentrations, contributing to dyslipidemias. [3]Moreover, conditions like nonalcoholic fatty liver disease involve proteins such asGlycosylphosphatidylinositol-specific phospholipase d(GPI-PLD), where its activity is implicated in disease pathology.[2]Identifying pQTLs for these critical biomolecules offers a powerful complementary method for improving our understanding of disease mechanisms and potentially informing therapeutic strategies.[1]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Signaling and Transcriptional Control
Section titled “Signaling and Transcriptional Control”Signaling pathways orchestrate cellular responses through receptor activation and intricate intracellular cascades. For instance, the melanocortin 4 receptor (MC4R) is implicated in energy balance, with common genetic variations near this receptor influencing waist circumference and insulin resistance.[16]Similarly, the leptin receptor (LEPR) plays a role in metabolic regulation, as genetic variability at its locus impacts plasma fibrinogen levels. [17] Receptor activation can lead to downstream signaling events, such as those involving the soluble interleukin-6 receptor (IL6R), where genetic variations affect its cleavage rates and circulating levels, contributing to metabolic syndrome pathways. [1] Transcriptional regulation is a critical aspect, with transcription factors like hepatic nuclear factor 1 (HNF-1) synergistically activating promoters, such as that of human C-reactive protein.[18]Furthermore, some proteins exhibit interactions with the thyroid hormone receptor that are dependent on the presence or absence of thyroid hormone, highlighting dynamic regulatory mechanisms.[19]
Metabolic Flux and Lipid Homeostasis
Section titled “Metabolic Flux and Lipid Homeostasis”Central to cellular function are metabolic pathways, which govern energy metabolism, biosynthesis, and catabolism. Lipid metabolism is particularly well-represented, with genetic variants in MLXIPL being associated with plasma triglycerides. [20] The mevalonate pathway, crucial for cholesterol biosynthesis, is regulated by enzymes like HMGCR, where common genetic variations can affect alternative splicing and consequently influence LDL-cholesterol levels. [21] Fatty acid desaturase genes (FADS cluster) are critical for the synthesis of polyunsaturated fatty acids, with variations linked to their circulating levels. [22] Lipid catabolism is influenced by factors such as angiopoietin-like protein 4 (ANGPTL4), a potent hyperlipidemia-inducing agent that inhibits lipoprotein lipase.[23]In glucose metabolism, glucokinase regulatory protein (GCKR) modulates glucokinase activity, and its variants are associated with altered fasting insulinemia, triacylglycerol levels, and type 2 diabetes risk.[24]Additionally, the facilitative glucose transporterSLC2A9 (GLUT9) functions as a renal urate anion exchanger, critically regulating blood urate levels and influencing conditions like gout.[25]
Protein Modifications and Regulatory Mechanisms
Section titled “Protein Modifications and Regulatory Mechanisms”Beyond transcriptional control, post-translational modifications and protein processing are pivotal regulatory mechanisms. Gene regulation itself is complex, with expression quantitative trait loci (eQTLs) demonstrating how genetic variation can globally influence gene expression levels. [26] At the protein level, specific genetic variants define protein quantitative trait loci (pQTLs), affecting aspects like the rates of cleavage of soluble receptors such as IL6R, the secretion rates of proteins like LPA, or even gene copy number variations for chemokines like CCL4. [1] Protein modifications play a crucial role, with phosphorylation being essential for proteins like Pleckstrin to associate with membranes and induce structural changes. [27] Ubiquitination, a process involving ubiquitin ligases like PJA1 and Parkin, targets proteins for degradation or alters their function, thus controlling protein homeostasis. [28] Furthermore, alternative splicing, exemplified by variations in HMGCR exon 13, represents a key post-transcriptional regulatory mechanism that diversifies protein isoforms and functions. [21]
Inter-Pathway Crosstalk and Disease Links
Section titled “Inter-Pathway Crosstalk and Disease Links”Biological systems exhibit extensive crosstalk between pathways and network interactions that lead to emergent properties, often relevant to disease pathogenesis. For instance, common genetic variants inLIPCimpact phosphatidylethanolamine levels and show weaker associations with conditions such as type 2 diabetes, bipolar disorder, and rheumatoid arthritis, suggesting intricate links between lipid metabolism and complex diseases.[14] The interplay between metabolism and inflammation is evident through IL6R and GCKR, which are associated with metabolic syndrome pathways and influence plasma C-reactive protein levels.[13] Variations in multiple gene loci, such as CPN1-ERLIN1-CHUK and PNPLA3-SAMM50, collectively influence plasma levels of liver enzymes like alanine-aminotransferase (ALT), highlighting a polygenic architecture governing liver function. [2] Understanding these metabolic phenotypes as intermediate traits can bridge the gap between genetic variations and the manifestation of complex diseases, thereby identifying potential therapeutic targets and informing personalized medicine strategies. [14] Dysregulation in these interconnected pathways underlies many common diseases, from dyslipidemia influenced by MLXIPL and ANGPTL4 [20]to gout associated withSLC2A9 variants. [29]
References
Section titled “References”[1] Melzer D et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, 2008.
[2] Yuan X, Waterworth D, Perry JRB, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83(5):548-55.
[3] Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40(2):161-9.
[4] Reiner AP et al. “Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein.”Am J Hum Genet, 2008.
[5] Benjamin EJ et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, 2007.
[6] Yang Q, Cupples LA, Dupuis J, et al. Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study. BMC Med Genet. 2007;8 Suppl 1:S9.
[7] Wallace C, et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”The American Journal of Human Genetics, 2008. PMID: 18179892.
[8] Pare G, et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genetics, 2008. PMID: 18604267.
[9] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nature Genetics, 2008. PMID: 19060906.
[10] Benyamin B, et al. “Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels.”The American Journal of Human Genetics, 2008. PMID: 19084217.
[11] Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2008;40(12):1394-402.
[12] Ling H et al. “Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study.”Obesity (Silver Spring), 2009.
[13] Ridker, P. M., et al. “Loci Related to Metabolic-Syndrome Pathways Including LEPR, HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women’s Genome Health Study.”American Journal of Human Genetics, 2008.
[14] Gieger C, Illig T, Prehn C, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008;4(11):e1000282.
[15] Doring, A., et al. “SLC2A9 Influences Uric Acid Concentrations with Pronounced Sex-Specific Effects.”Nature Genetics, 2008.
[16] Chambers, J.C., et al. “Common genetic variation near MC4R is associated with waist circumference and insulin resistance.”Nat. Genet., vol. 40, 2008, pp. 716-718.
[17] Zhang, Y.Y., et al. “Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen.”Ridker et al. 2008, Am J Hum Genet., vol. 82, 2007, pp. 1185-92. (Referencing from Ridker et al. 2008)
[18] Toniatti, C., et al. “Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.”EMBO J., vol. 9, 1990, pp. 4467-4475.
[19] Lee, J.W., et al. “Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor.”Mol. Endocrinol., vol. 9, 1995, pp. 243-254.
[20] Kooner, J.S., et al. “Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.” Nat Genet, vol. 40, 2008, pp. 149-51.
[21] Burkhardt, R., et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, 2008, pp. 2072-8.
[22] Malerba, G., et al. “SNPs of the FADS Gene Cluster are Associated with Polyunsaturated Fatty Acids in a Cohort of Patients with Cardiovascular Disease.”Lipids, vol. 43, 2008, pp. 289–299.
[23] Yoshida, K., et al. “Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.”J. Lipid Res., vol. 43, 2002, pp. 1770-1772.
[24] Garcia-Herrero, C.M., et al. “Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mecha-nisms of glucokinase activity.”Diabetologia, vol. 50, 2007, pp. 325-333.
[25] Li, S., et al. “The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.”PLoS Genet, vol. 3, 2007, p. e194.
[26] Dixon, A.L., et al. “A genome-wide association study of global gene expression.” Nat Genet, vol. 10, 2007, pp. 1202-1207.
[27] Ma, A.D., et al. “Pleckstrin associates with plasma membranes and induces the formation of membrane projections: requirements for phosphorylation and the NH2-terminal PH domain.” J Cell Biol, vol. 136, 1997, pp. 1071-1071.
[28] Yu, P., et al. “PJA1, encoding a RING-H2 finger ubiquitin ligase, is a novel human X chromosome gene abundantly expressed in brain.” Genomics, vol. 79, 2002, pp. 869-874.
[29] Vitart, V., et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, vol. 40, 2008, pp. 432-6.